Comparative study on the clinical and virological characteristics among patients with single occult hepatitis B virus (HBV), single occult hepatitis C virus (HCV) and occult HBV and HCV dual infection.
Occult hepatitis B virus (HBV) and occult hepatitis C virus (HCV) infection are two recently described different forms of HBV and HCV infections. This work compares the clinical, virologic, and histologic characteristics of patients with occult dual infection to those of patients with single occult HBV or HCV infection. Seventy-six patients with abnormal liver function tests of unknown etiology (serum HBsAg, anti-HCV, HBV-DNA, and HCV-RNA negative) were included in the study. Viral genomes were tested in liver by real-time PCR and confirmed by in situ hybridization. Of the 76 patients, 17 had occult HBV infection (intrahepatic HBV-DNA positive, HCV-RNA negative), 35 had occult HCV infection (intrahepatic HCV-RNA positive, HBV-DNA negative) and 24 occult dual infection (intrahepatic HCV-RNA and HBV-DNA). No differences among the three groups were found regarding clinical and epidemiologic data. The median load of intrahepatic genomic and antigenomic HCV-RNA strands was similar between single occult HCV infection and occult HBV and HCV dual infection. The percentage of HCV-infected hepatocytes did not differ between these groups. In occult single HBV infection, intrahepatic levels of HBV-DNA and percentage of HBV-infected hepatocytes were similar to the group of patients with occult dual infection. Finally, no differences were found in histological liver damage among the three groups. In conclusion, liver disease in patients with occult dual infection was not more severe than in patients with single occult HBV or occult HCV infection. Moreover, in occult dual infection there is no a reciprocal inhibition of the viral genomes.
Castillo
Inmaculada
I
Fundación para el Estudio de las Hepatitis Virales, Madrid, Spain.
Rodríguez-Iñigo
Elena
E
López-Alcorocho
Juan Manuel
JM
Bartolomé
Javier
J
Pardo
Margarita
M
Carreño
Vicente
V
D000328:Adult; D004279:DNA, Viral / Q000032:analysis / Q000097:blood; D005260:Female; D016174:Hepacivirus; D006509:Hepatitis B / Q000150:complications / Q000473:pathology* / Q000503:physiopathology / Q000821:virology*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus; D006526:Hepatitis C / Q000150:complications / Q000473:pathology* / Q000503:physiopathology / Q000821:virology*; D018937:Hepatitis C Antibodies / Q000097:blood; D022781:Hepatocytes / Q000821:virology; D006801:Humans; D017403:In Situ Hybridization; D008099:Liver / Q000821:virology; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D012367:RNA, Viral / Q000032:analysis / Q000097:blood; D020133:Reverse Transcriptase Polymerase Chain Reaction
D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D018937:Hepatitis C Antibodies; D012367:RNA, Viral